The discovery of aberrant JAK/STAT signaling in MPNs led to the clinical use of JAK inhibitors becoming a standard treatment for intermediate- and high-risk MF and refractory PV.4 The JAK1/2 inhibitor ruxolitinib has become a centerpiece of MPN treatment over the last decade. Here, JAK1 is linked to acquired polycythemia vera.